In contrast, metanalysis by Song and colleagues confirmed that loss of IFNγ signalling in tumour cells made tumours more susceptible to the host immune system in mouse syngeneic models despite causing resistance to immune effector cells in vitro, and revealed that patient tumours developing mutations in IFNγ signalling before treatment were more likely to respond to ICBT40. Here, IFNG is linked to neoplasm.